Files and links (1)
Published, Version of Record (VoR)CC BY-NC V4.0, Open
Journal article
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
Rheumatology (Oxford, England), v 60(5), pp 2109-2121
14 May 2021
PMID: 33844022
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Abstract
Objective
The efficacy of the novel interleukin (IL)-23p19 inhibitor guselkumab for psoriatic arthritis (PsA) has recently been demonstrated in two phase 3 trials (DISCOVER-1 & -2) but has not been evaluated vs other targeted therapies for PsA. The objective was to compare guselkumab to targeted therapies for PsA for safety and joint and skin efficacy through network meta-analysis (NMA).
Methods
A systematic literature review was conducted in January 2020 to identify randomized controlled trials. Bayesian NMAs were performed to compare treatments on American College of Rheumatology (ACR) 20/50/70 response, mean change from baseline in van der Heijde-Sharp (vdH-S) score, Psoriasis Area Severity Index (PASI) 75/90/100 response, adverse events (AEs) and serious adverse events (SAEs).
Results
Twenty-six phase 3 studies evaluating 13 targeted therapies for PsA were included. For ACR 20 response, guselkumab 100 mg every 8 weeks (Q8W) was comparable to IL-17A inhibitors and subcutaneous tumor necrosis factor (TNF) inhibitors. Similar findings were observed for ACR 50 and 70. For vdH-S score, guselkumab Q8W was comparable to other agents except intravenous TNF therapies. Results for PASI 75 and PASI 90 response suggested guselkumab Q8W was better than most other agents. For PASI 100, guselkumab Q8W was comparable to other active agents. For AEs and SAEs, guselkumab Q8W ranked highly but comparative conclusions were uncertain. Similar results were observed for all outcomes for guselkumab 100 mg every four weeks.
Conclusions
In this NMA, guselkumab demonstrated favorable arthritis efficacy comparable to IL-17A and subcutaneous TNF inhibitors while offering better PASI response relative to many other treatments.
Metrics
Details
- Title
- Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
- Creators
- Philip J Mease - Swedish Medical Center-Providence St. Joseph Health and University of Washington, Seattle, WA, USA.Iain B McInnes - University of GlasgowLai-Shan Tam - Chinese University of Hong KongKiefer Eaton - EVERSANASteve Peterson - Janssen Global Services LLC, Immunology, Global Commercial Strategy Organization, Horsham, PA, USAAgata Schubert - Janssen-CilagSoumya D Chakravarty - Drexel UniversityAnna Parackal - EVERSANAChetan S Karyekar - Janssen Global Services LLC, Immunology, Global Commercial Strategy Organization, Horsham, PA, USASandhya Nair - JanssenWolf-Henning Boehncke - Geneva University Hospitals, Department of Medicine, Geneva, Switzerland.Christopher Ritchlin - University of Rochester
- Publication Details
- Rheumatology (Oxford, England), v 60(5), pp 2109-2121
- Publisher
- Oxford University Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Rheumatology
- Web of Science ID
- WOS:000656146200026
- Scopus ID
- 2-s2.0-85106553264
- Other Identifier
- 991019167458004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Rheumatology